Literature DB >> 16436742

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.

Armin Stucki1, Peter Gerber, Fernando Acosta, Marianne Cottagnoud, Philippe Cottagnoud.   

Abstract

The penetration of telavancin was 2% into inflamed meninges and ca. 1 per thousand into noninflamed meninges after two intravenous injections (30 mg/kg of body weight). In experimental meningitis, telavancin was significantly superior to vancomycin combined with ceftriaxone against a penicillin-resistant pneumococcal strain. Against a methicillin-sensitive staphylococcal strain, telavancin was slightly but not significantly superior to vancomycin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436742      PMCID： PMC1366883          DOI： 10.1128/AAC.50.2.770-773.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.

Authors:  C M Gerber; M Cottagnoud; K A Neftel; M G Täuber; P Cottagnoud
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-12       Impact factor: 3.267

2.  Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

Authors:  Gary V Doern; Sandra S Richter; Ashley Miller; Norma Miller; Cassie Rice; Kristopher Heilmann; Susan Beekmann
Journal:  Clin Infect Dis       Date:  2005-06-07       Impact factor: 9.079

Review 3.  Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

Authors:  Françoise Van Bambeke
Journal:  Curr Opin Pharmacol       Date:  2004-10       Impact factor: 5.547

Review 4.  Global antibiotic resistance in Streptococcus pneumoniae.

Authors:  Dieter Adam
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

5.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

Review 6.  Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases.

Authors:  A G Jensen; F Espersen; P Skinhøj; V T Rosdahl; N Frimodt-Møller
Journal:  Arch Intern Med       Date:  1993-08-23

7.  Staphylococcus aureus meningitis: a broad-based epidemiologic study.

Authors:  L S Schlesinger; S C Ross; D R Schaberg
Journal:  Medicine (Baltimore)       Date:  1987-03       Impact factor: 1.889

Review 8.  Management of pneumococcal meningitis.

Authors:  Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2002-06       Impact factor: 2.129

9.  Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.

Authors:  Anna King; Ian Phillips; Koné Kaniga
Journal:  J Antimicrob Chemother       Date:  2004-03-17       Impact factor: 5.790

10.  Staphylococcus aureus meningitis: review of 28 cases.

Authors:  J H Kim; C van der Horst; C D Mulrow; G R Corey
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct
View more
  7 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

Review 2.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 3.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

4.  Treatment of Drug-resistant Pneumococcal Meningitis.

Authors:  Nida Hameed; Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

5.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

6.  In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.

Authors:  Kerry L LaPlante; Leonard A Mermel
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 7.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.